Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency

@f2harrell @lakens @david_colquhoun I think you're closer to 1. I'm not sure how to resolve that here. I know that regulators care, or at least cared 10 years about severity. https://t.co/yWo06QBFSM

RT @posch_m: This paper follows-up on the fate of the proposed adaptive trials identified in our review on EMA Scientific Advice Procedures…

RT @posch_m: This paper follows-up on the fate of the proposed adaptive trials identified in our review on EMA Scientific Advice Procedures…

This paper follows-up on the fate of the proposed adaptive trials identified in our review on EMA Scientific Advice Procedures https://t.co/EkTghfgSW5